GSK's gepotidacin shows 92.6% success in uncomplicated urogenital gonorrhoea phase three trial, matching leading combination therapy.
GSK reports positive results from a phase three trial of gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea. The treatment showed a 92.6% success rate, matching the leading combination therapy, and its safety profile was consistent with previous trials. Gonorrhoea, with 82 million new cases annually worldwide, sees increasing resistance to current therapies.
April 17, 2024
4 Articles